NCT07924332
Retlirafusp Alfa or Adebrelimab Plus SOX as Neoadjuvant Therapy for HER2-Negative Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Pathologic Complete Response (pCR) Rate
Timeframe: After D2 radical surgery (within 8 weeks after neoadjuvant completion)
Secondary (5)
R0 Resection Rate
Event-Free Survival(EFS)
Disease-Free Survival(DFS)
Overall Survival(OS)
Safety and Tolerability
Arms and interventions
Retlirafusp Alfa Plus SOXExperimental
Retlirafusp alfa plus SOX for 3 preoperative 21-day cycles, followed by D2 radical surgery, then retlirafusp alfa plus SOX for 5 postoperative cycles, followed by retlirafusp alfa alone for 9 cycles. Retlirafusp alfa may be given for a maximum of 17 cycles in total.
Adebrelimab Plus SOXExperimental
Adebrelimab plus SOX for 3 preoperative 21-day cycles, followed by D2 radical surgery, then adebrelimab plus SOX for 5 postoperative cycles, followed by adebrelimab alone for 9 cycles. Adebrelimab may be given for a maximum of 17 cycles in total.
Drugs: Retlirafusp Alfa Plus Chemotherapy, Adebrelimab Plus chemotherapy